EUCTR2014-002841-23-ES
Active, not recruiting
Phase 1
A Phase I/IIa Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With Respiratory Syncytial Virus Lower Respiratory Tract Infection, Consisting of an Open-label Lead in Part Followed by a Double-blind, Placebo-controlled Part, to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171, Administered Via Inhalation, in Addition to Standard of Care
Overview
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Ablynx NV
- Enrollment
- 35
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1\. Subject is a male or female infant or toddler aged 5 months to \< 24 months.
- •2\. Subject is otherwise healthy, but hospitalised for and clinically diagnosed with RSV LRTI (bronchiolitis or broncho\-pneumonia), i.e., showing typical clinical signs and symptoms such as tachypnoea, wheezing, cough, crackles, use of accessory muscles, and/or nasal flaring.
- •3\. Subject has appearance of upper or lower respiratory tract infection symptoms that are likely related to RSV infection (e.g., rhinitis) within ? 4 days at the time of screening.
- •4\. Subject has a positive RSV diagnostic test .
- •5\. Subject is expected to have to stay in the hospital for at least 24 hours (according to the Investigator?s judgement at screening).
- •6\. Subject has normal psychomotor development (according to the Investigator?s judgement at screening).
- •7\. Subject?s gestational age was \> 37 weeks.
- •8\. Parent(s)/legal guardian(s) are able and willing to provide written informed consent.
- •9\. The subject and parent(s)/legal guardian(s) are able and willing to comply with the study protocol.
- •Are the trial subjects under 18? yes
Exclusion Criteria
- •1\. Subject has history of wheezing (i.e., \>3 previous episodes of wheezing), as reported by the parent(s)/legal guardian(s), or according to the Investigator?s judgement at screening.
- •2\. Subject is known to have significant comorbidities, including gastro\-oesophageal reflux disease, genetic disorders (e.g., trisomy 21\), cardiopulmonary diseases (e.g., haemodynamically significant congenital heart disease, or bronchopulmonary dysplasia), any hereditary or acquired metabolic (bone) diseases, haematological or other malignancy, or is known to be human immunodeficiency virus (HIV) positive.
- •3\. Subject is known to be immunocompromised.
- •4\. Subject has any presence of active moderate to severe atopic dermatitis (according to the Investigator?s judgement at screening).
- •5\. Subject has any known history or presence of food allergy.
- •6\. Subject is suspected of having a clinically relevant infection other than RSV.
- •7\. Subject has a history of any ventilation or respiratory support, including the neonatal period.
- •8\. Subject has significant oral and/or maxillofacial malformations.
- •9\. Subject is critically ill and/or is expected to require invasive mechanical ventilation or noninvasive respiratory support (e.g., continuous or bilevel positive airway pressure) within 24 hours (according to the Investigator?s judgement at screening), with the exception of O2 supplementation via nasal cannula, simple face mask, or headbox.
- •10\. Subject has received 1 or more doses of palivizumab at any time prior to screening, or has received treatment with any antiviral therapy for RSV (e.g., ribavirin or i.v. immunoglobulin) within 1 month prior to screening.
Investigators
Similar Trials
Completed
Phase 2
A multicenter phase II study for previouly untreated advanced stage peripheral T-cell lymphoma evaluating efficacy and safety of combination chemotherapy with THP-COP regimepreviouly untreated advanced stage peripheral T-cell lymphomaJPRN-UMIN000014902Hematological Malignancy Study Group40
Completed
Not Applicable
A phase I-Ib/II, open-label, multi-center study of the safety and efficacy of MBG453 as single agent and in combination with PDR001 in adult patients with advanced malignanciesadvanced cancerlungcancermelanoma10027655NL-OMON53097ovartis33
Active, not recruiting
Phase 1
An interventional study of MBG453 as single agent and in combination with PDR001 in patients with advanced malignanciesSolid tumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-002354-12-NLovartis Pharma Services AG252
Active, not recruiting
Phase 1
An interventional study of MBG453 alone and in combination with PDR001 in patients with advanced malignanciesSolid tumorsTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-002354-12-DEovartis Pharma Services AG250
Completed
Phase 1
Phase I-Ib/II study of MBG453 as single agent and in combination with PDR001 in patients with advanced malignancies.advanced solid tumorJPRN-jRCT2080223302ovartis Pharma. K.K.21